GlassScriptPhysician profile
Natalie M Mitzel
NPI 1528360583
$2,947.43
in general payments reported to CMS, 2019-2025
44 companies · $809 in 2025
The $809 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $368 · 2024: $1,770 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.49 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $278.46 | 2023-2025 | |
| Daiichi Sankyo INC. | $276.01 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Astrazeneca Pharmaceuticals LP | $182.07 | 2023-2025 | Enhertu, Calquence, Lynparza |
| Stemline Therapeutics INC. | $164.83 | 2023-2025 | Orserdu, Elzonris |
| Sobi, INC | $158.11 | 2024 | |
| Merck Sharp & Dohme LLC | $146.96 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $131.25 | 2023-2025 | |
| Genentech USA, INC. | $119.36 | 2023-2025 | Itovebi, Tecentriq, Polivy |
| Eisai INC. | $111.03 | 2023-2024 | |
| Janssen Biotech, INC. | $109.68 | 2023-2024 | Darzalex, Rybrevant, Tecvayli |
| Lilly USA, LLC | $95.85 | 2024 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $89.00 | 2024-2025 | Iclusig, Alunbrig |
| Genmab U.S., INC. | $71.34 | 2024-2025 | Tivdak, Epkinly |
| Pharmacosmos Therapeutics INC. | $68.44 | 2024-2025 | Monoferric |
| Karyopharm Therapeutics INC. | $67.51 | 2023-2024 | Xpovio |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67.13 | 2024-2025 | |
| Octapharma USA, INC. | $63.70 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Astellas Pharma US INC | $50.75 | 2024-2025 | Vyloy, Xospata |
| Novocure INC. | $49.73 | 2024-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Servier Pharmaceuticals LLC | $49.10 | 2023-2025 | |
| Pfizer INC. | $48.11 | 2024-2025 | |
| Incyte Corporation | $42.69 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Myriad Genetic Laboratories, INC. | $41.36 | 2024-2025 | Myrisk |
| Abbvie INC. | $40.84 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.14 | 2024-2025 | Gilotrif |
| Regeneron Healthcare Solutions, INC. | $33.21 | 2024-2025 | Libtayo |
| Glaxosmithkline, LLC. | $26.40 | 2023 | Jemperli, Zejula |
| Sumitomo Pharma America, INC. | $22.13 | 2024 | Orgovyx |
| Morphosys, US INC. | $21.86 | 2024 | Monjuvi |
| Iovance Biotherapeutics, INC. | $21.20 | 2025 | Amtagvi |
| Celgene Corporation | $20.90 | 2025 | Reblozyl |
| Organon LLC | $20.35 | 2024 | |
| Adc Therapeutics America, INC. | $20.21 | 2024 | |
| Kite Pharma, INC. | $19.98 | 2025 | Yescarta |
| Deciphera Pharmaceuticals INC. | $19.62 | 2025 | Qinlock, Tgct |
| Amneal Pharmaceuticals LLC | $19.29 | 2024 | Avastin |
| Gilead Sciences, INC. | $18.95 | 2025 | Trodelvy |
| Emd Serono, INC. | $18.87 | 2025 | |
| Exelixis INC. | $18.69 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $18.25 | 2025 | Enjaymo |
| Rigel Pharmaceuticals, INC. | $16.71 | 2024 | Rezlidhia, Tavalisse |
| Aveo Pharmaceuticals, INC. | $16.70 | 2024 | |
| Janssen Scientific Affairs, LLC | $16.48 | 2025 | Darzalex, Tecvayli, Talvey |
| Puma Biotechnology, INC. | $15.18 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Mitzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.